EUVIMEDEUVIMED entdecken
Crossref

Clinical Outcomes and Implications of Radioactive Iodine Therapy on Cancer-specific Survival in WHO Classification of FTC

Genpeng Li, Ziyang Ye, Tao Wei, Jingqiang Zhu, Zhihui Li, Jianyong Lei iD

The Journal of Clinical Endocrinology & Metabolism · 2024

DOI: 10.1210/clinem/dgae122 ↗

Kurz gefasst

Fachartikel in der Zeitschrift The Journal of Clinical Endocrinology & Metabolism, 2024. Verfasst von Genpeng Li und 5 weiteren Autor:innen. Beteiligte Einrichtung: Division of Thyroid Surgery, Department of General Surgery, West China Hospital, Sichuan University, Chengdu, 610041, China. Hauptthemen laut MEDLINE: Iodine Radioisotopes, Thyroid Neoplasms, Adenocarcinoma, Follicular. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 24 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

The clinical outcomes and implications of radioactive iodine therapy (RAIT) on cancer-specific survival (CSS) in World Health Organization classification of follicular thyroid carcinoma (FTC) are not well established. Material and Methods The data of eligible patients with minimally invasive FTC (mi-FTC), encapsulated angioinvasive FTC (ea-FTC), or widely invasive FTC (wi-FTC) between 2000 and 2020 were extracted from the Surveillance, Epidemiology, and End Results database. CSS, the primary outcome, was compared among the 3 subtypes of patients with FTC before and after adjusting for differences using propensity score matching (PSM). The patients with FTC in different subtypes were then divided into 2 groups: the RAIT group and the no-RAIT group. Cox proportional hazards regression analyses were applied to discover the relationships of factors associated with CSS in the each PSM cohort.

Results

A total of 2433 patients with mi-FTC, 216 patients with ea-FTC, and 554 patients with wi-FTC were enrolled in the original cohorts, respectively. Patients with mi-FTC or ea-FTC had similar CSS (P = .805), which was better than that of patients with wi-FTC (P < .001; P = .021). Cox proportional hazards regression analysis revealed that RAIT was not associated with improved CSS in either the mi-FTC PSM cohort (hazard ratio [HR], 1.21; 95% CI, .46-3.18; P = .705) or the wi-FTC PSM cohort (HR, 0.56; 95% CI, .35-1.08; P = .086). However, subgroup analysis demonstrated that patients with wi-FTC and N1 stage (HR, 0.44; 95% CI, .20-.99; P = .018) or M1 stage (HR, 0.25; 95% CI, .11-.53; P < .001) could gain CSS advantage from RAIT.

Conclusion

The RAIT can provide a CSS advantage for patients with wi-FTC who with N1-stage or M1-stage disease.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Iodine RadioisotopesThyroid NeoplasmsAdenocarcinoma, FollicularHumansFemaleMaleMiddle AgedAdultWorld Health OrganizationSEER ProgramAgedTreatment OutcomePrognosisSurvival RateRetrospective Studies

Stichwörter der Autor:innen

cancer-specific survivalfollicular thyroid cancerradioactive iodine

Substanzen

Iodine Radioisotopes

Autor:innen und Institutionen

  • Division of Thyroid Surgery, Department of General Surgery, West China Hospital, Sichuan University, Chengdu, 610041, China.
  • The Laboratory of Thyroid and Parathyroid Disease, Frontiers Science Center for Disease-related Molecular Network, West China Hospital, Sichuan University, Chengdu 610213, China.

ORCID-Profile: Jianyong Lei

Zitieren

APA

Li, G., Ye, Z., Wei, T., Zhu, J., Li, Z., & Lei, J. (2024). Clinical Outcomes and Implications of Radioactive Iodine Therapy on Cancer-specific Survival in WHO Classification of FTC. The Journal of Clinical Endocrinology & Metabolism. https://doi.org/10.1210/clinem/dgae122

Vancouver

Li G, Ye Z, Wei T, Zhu J, Li Z, Lei J. Clinical Outcomes and Implications of Radioactive Iodine Therapy on Cancer-specific Survival in WHO Classification of FTC. The Journal of Clinical Endocrinology & Metabolism. 2024. doi:10.1210/clinem/dgae122

BibTeX
@article{Li2024,
  author = {Li, Genpeng and Ye, Ziyang and Wei, Tao and Zhu, Jingqiang and Li, Zhihui and Lei, Jianyong},
  title = {Clinical Outcomes and Implications of Radioactive Iodine Therapy on Cancer-specific Survival in WHO Classification of FTC},
  journal = {The Journal of Clinical Endocrinology & Metabolism},
  year = {2024},
  doi = {10.1210/clinem/dgae122}
}
Kostenlos starten →